Outset Medical Files 8-K with Material Agreements
Ticker: OM · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1484612
Sentiment: neutral
Topics: material-agreement, financial-update, equity-securities
TL;DR
Outset Medical dropped an 8-K on Jan 3rd covering material agreements and financials.
AI Summary
On January 3, 2025, Outset Medical, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers results of operations, unregistered sales of equity securities, and Regulation FD disclosures. The company is incorporated in Delaware and its principal executive office is located at 3052 Orchard Drive, San Jose, California.
Why It Matters
This 8-K filing provides crucial updates on Outset Medical's material agreements and financial condition, impacting investor understanding of the company's current operational status.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant corporate events, but this specific filing appears to be a routine update rather than a major crisis.
Key Players & Entities
- Outset Medical, Inc. (company) — Registrant
- January 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 3052 Orchard Drive, San Jose, California 95134 (address) — Principal Executive Office
FAQ
What specific material definitive agreement was entered into by Outset Medical, Inc. on or around January 3, 2025?
The 8-K filing indicates an 'Entry into a Material Definitive Agreement' as an item of disclosure, but the specific details of the agreement are not provided in the provided text.
What are the key aspects of Outset Medical's results of operations and financial condition reported in this 8-K?
The filing lists 'Results of Operations and Financial Condition' as an item, but the specific financial details or operational results are not detailed in the provided excerpt.
Does the 8-K filing mention any unregistered sales of equity securities by Outset Medical?
Yes, 'Unregistered Sales of Equity Securities' is listed as an item of disclosure in the 8-K filing.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
The Regulation FD Disclosure item suggests that the company is providing information to the public in compliance with fair disclosure rules, potentially related to material non-public information.
What is the former name of Outset Medical, Inc. and when did the name change occur?
The former name of Outset Medical, Inc. was Home Dialysis Plus, Ltd., and the date of the name change was February 19, 2010.
Filing Stats: 2,658 words · 11 min read · ~9 pages · Grade level 13.3 · Accepted 2025-01-06 09:36:58
Key Financial Figures
- $0.001 — registered Common Stock, par value of $0.001 per share OM The Nasdaq Stock Marke
- $200.00 — Preferred Stock at a purchase price of $200.00 per share for an aggregate purchase pri
- $172.7 million — gregate purchase price of approximately $172.7 million. Institutional investors are expected t
- $168.8 m — tional investors are expected to invest $168.8 million, and following the approval of th
- $3.9 million — ard of Directors are expected to invest $3.9 million. The Company expects to use the net pro
- $125.0 million — up to an aggregate principal amount of $125.0 million pursuant to a credit agreement and guar
- $125.0 m — an aggregate principal amount of up to $125.0 million, comprised of (i) a term loan of
- $100.0 million — illion, comprised of (i) a term loan of $100.0 million (the "Initial Term Loan") to be funded
- $25.0 million — (ii) a delayed draw term loan of up to $25.0 million (the "Delayed Draw Loan"). The Initial
- $1.0 million — refundable closing fee in the amount of $1.0 million in respect of the Initial Term Loan on
- $250,000 — refundable closing fee in the amount of $250,000 in respect of the Delayed Draw Loan, to
- $10.0 million — tain a minimum cash balance of at least $10.0 million in accounts subject to control agreemen
Filing Documents
- d900977d8k.htm (8-K) — 45KB
- d900977dex101.htm (EX-10.1) — 220KB
- d900977dex102.htm (EX-10.2) — 216KB
- d900977dex103.htm (EX-10.3) — 99KB
- d900977dex104.htm (EX-10.4) — 624KB
- d900977dex991.htm (EX-99.1) — 13KB
- g900977g0105183747032.jpg (GRAPHIC) — 3KB
- 0001193125-25-001911.txt ( ) — 1628KB
- om-20250103.xsd (EX-101.SCH) — 3KB
- om-20250103_lab.xml (EX-101.LAB) — 17KB
- om-20250103_pre.xml (EX-101.PRE) — 11KB
- d900977d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This report and the exhibit attached hereto contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, the use of proceeds from, and closing of, the private placement financing and the debt financing; statements about anticipated benefits of the financings, including the company's expectations that the funds will capitalize it through cashflow breakeven; as well as statements about the company's unaudited results of operations, including fourth quarter and full year 2024 revenue. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this report and the exhibit attached hereto Company's include risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the private placement and the debt financing, as well as other risks described in the Risk Factors section of the Company's public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the ex
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: No. Exhibit 10.1 Form of Securities Purchase Agreement, dated as of January 3, 2025 between Outset Medical, Inc. and certain of the Investors 10.2 Form of Securities Purchase Agreement, dated as of January 3, 2025 between Outset Medical, Inc. and certain members of management and certain directors 10.3 Form of Registration Rights Agreement, dated as of January 3, 2025 between Outset Medical, Inc. and the Investors 10.4# Credit Agreement and Guaranty, dated as of January 3, 2025, by and among Outset Medical, Inc. as the borrower and Perceptive Credit Holdings IV, LP, as the initial lender and the administrative agent 99.1 Press Release issued by Outset Medical, Inc. dated January 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) # Portions of the exhibit have been excluded because it is both not material and is the type of information that the registrant treats as private or confidential. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 6, 2025 Outset Medical, Inc. By: /s/ Nabeel Ahmed Name: Nabeel Ahmed Title: Chief Financial Officer